Pre-made Pacanalotamab benchmark antibody ( Bispecific scFv, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pacanalotamab is an anti-BCMA-anti-CD3-bispecific-antibody, where the bispecific T-cell engager (BiTE) binds to the CD3 epsilon subunit of the T cell receptor complex on T-cells and to B-cell maturation antigen (BCMA), a membrane-bound receptor on plasma cells, resulting in activation of T cells against BCMA.
| Products Name (INN Index) | Pre-Made Pacanalotamab biosimilar, Bispecific scFv, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Pacanalotamab |
| Target | TNFRSF17,CD3E |
| Format | Bispecific scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | na;na |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Amgen |
| Conditions Approved | NA |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | NA |
| Development Tech | BiTE Technology |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF17,CD3E |
| Package |
